Gerber to Chair Institutional Conflcit of Interest Committee
June 27, 2012 – Dr. David Gerber, MD, FACS, Chief of Abdominal Transplant Division, has been appointed as chair of the Institutional Conflict of Interest Committee at UNC Chapel Hill.
June 27, 2012 – Dr. David Gerber, MD, FACS, Chief of Abdominal Transplant Division, has been appointed as chair of the Institutional Conflict of Interest Committee at UNC Chapel Hill.
May 1, 2012 – Dr. Nancy Demore, associate professor of surgical oncology, will be published in the May 1st edition of ASCO Post.
April 30, 2012 – Dr. David Gerber, UNC Transplant Surgery, was the co-author of a study that shows that liver transplants performed at night or on weekends do not adversely affect patient or graft survival.
Richard H. Feins, M.D. April 21, 2012 – Richard H. Feins, M.D., spoke about “How ‘Good Enough’ Became Acceptable in Surgical Training” at the Mayo Clinic in Rochester, MN, on April 21, 2012. Dr. Feins was the 2012 O.T. Clagett visiting professor at the Mayo Clinic. Dr. Feins, a thoracic surgeon and professor of surgery … Read more
April 9, 2012 – Ashley McKnight, of Forsyth County, NC, was born with cystic fibrosis. She got new lungs in a double-lung transplant operation in 2009, when she was 14. However, her body began rejecting the lungs and she went … Continued
February 29, 2012 — Dr. Andy Kiser, chief of the UNC Division of Cardiothoracic Surgery, along with several others, is working to develop a new UNC/Rex Heart Valve Center that will offer a minimally-invasive aortic valve procedure colleagues
January 30, 2012 — The University of North Carolina School of Medicine Division of Urology is pleased to announce their newest residency members, James “Abram” McBride, Maxim “Max” McKibben, and Josip Vukina, matched through the 2012 AUA Urology Match. They will join us as PGY1 urology residents starting June 24, 2012.
November 17, 2011 – The Department of Defense has awarded Entegrion, of which Dr. Preston Rich is Vice President and Chief Medical Officer, $43.7 million to develop a plasma-derived drug that may someday be a substitute for fresh frozen plasma.